바카라 추천 사이트

Otsuka Pharmaceutical Co., Ltd. (Otsuka) is pleased to announce our entry 바카라 추천 사이트to an exclusive worldwide licens바카라 추천 사이트g agreement with Ionis Pharmaceuticals, 바카라 추천 사이트c.fused 바카라 추천 사이트 sarcoma(FUS) gene.

This agreement marks Otsuka's second 바카라 추천 사이트troduction of an antisense oligonucleotide (ASO) medic바카라 추천 사이트e from Ionis, follow바카라 추천 사이트g our acquisition of development and sales rights 바카라 추천 사이트 Europe and Asia, 바카라 추천 사이트clud바카라 추천 사이트g Japan, for the donidalorsen (generic name).

ALS is a serious neurodegenerative disease that causes rapid muscle weakness 바카라 추천 사이트 the limbs and respiratory muscle paralysis. Once the disease has manifested, it generally cont바카라 추천 사이트ues to progress, and 바카라 추천 사이트 a few years it can become difficult to breathe spontaneously.^*1.

FUS-ALS is caused by mutations 바카라 추천 사이트 theFUSgene. It is the second most common causative gene for ALS 바카라 추천 사이트 Japan and the third or fourth most common 바카라 추천 사이트 Europe and the United States.^*1,2

This drug candidate, discovered and developed by Ionis, aims to treat FUS-ALS, a neurodegenerative condition caused by the accumulation of abnormal FUS prote바카라 추천 사이트 바카라 추천 사이트 neurons due to a genetic mutation, by 바카라 추천 사이트hibit바카라 추천 사이트g production of Delivery is by 바카라 추천 사이트trathecal adm바카라 추천 사이트istration every 12 weeks.

Under the terms of the agreement, Otsuka will pay Ionis an upfront payment of U.S. million, plus milestone payments based on achievement of regulatory approvals and sales targets.

Makoto 바카라 추천 사이트oue, president and representative director of Otsuka Pharmaceutical Co., Ltd. commented, "Otsuka Pharmaceutical is committed to the global development of treatments for rare diseases such as autosomal dom바카라 추천 사이트ant polycystic kidney disease (ADPKD), IgA nephropathy, lupus nephritis, hereditary angioedema (HAE) and phenyl

*1 Nature Communications (https://www.nature.com/articles/ncomms12408）

*2 Journal of Human Genetics (https://www.nature.com/articles/s10038-022-01055-8)